Absci's Innovative Partnership with Memorial Sloan Kettering to Develop AI-Driven Cancer Treatments
Monday, 12 August 2024, 10:53
Overview of the Partnership
Absci Corp. has entered into a partnership with Memorial Sloan Kettering Cancer Center to create new cancer therapies.
Therapeutics Development
The collaboration aims to produce up to six novel therapeutics using cutting-edge AI technology.
Technology Impact
Utilizing generative AI in drug discovery is expected to enhance the efficiency of the therapeutics development process.
Conclusion
This partnership exemplifies how innovation and technology can play a pivotal role in improving outcomes in cancer treatment.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.